Moleculin Biotech is trading at $0.50, up 14.75% in pre-market ahead of its scheduled presentation; available sources do not establish a causal link. - The October 14 Maxim Growth Summit presentation will discuss the oncology pipeline and clinical progress; the announcement was dated October 7. - The latest listed release reports completed Part A enrollment in the MIRACLE trial and a comprehensive data readout planned for Q1 2027; no new October 14 result or announcement was found.